Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Factors driving availability of COVID-19 convalescent plasma: Insights from a demand, production and supply model

View ORCID ProfileW. Alton Russell, View ORCID ProfileEduard Grebe, View ORCID ProfileBrian Custer
doi: https://doi.org/10.1101/2020.10.25.20219170
W. Alton Russell
1Vitalant Research Institute, San Francisco, CA, USA
2Department of Management Science and Engineering, Stanford University, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for W. Alton Russell
Eduard Grebe
1Vitalant Research Institute, San Francisco, CA, USA
3Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eduard Grebe
  • For correspondence: EGrebe@vitalant.org
Brian Custer
1Vitalant Research Institute, San Francisco, CA, USA
3Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Brian Custer
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background COVID-19 Convalescent Plasma (CCP) is a promising treatment for COVID-19. Blood collectors have rapidly scaled up collection and distribution programs.

Methods We developed a detailed simulation model of CCP donor recruitment, collection, production and distribution processes. Simulations based on epidemics in 11 U.S. states, in which key parameters were varied over wide ranges, allowed identification of the drivers of ability to calibrate collections capacity and ability to meet demand for CCP.

Results Changes in collection capacity utilization lagged increases and decreases in COVID-19 hospital discharges, and never exceeded 75% in most simulations. Demand could be met for most of the simulation period in most simulations, but in states with early sharp increases in hospitalizations a substantial portion of demand went unmet during these early peaks. Modeled second wave demand could generally be met with stockpiles established during first epidemic peaks. Apheresis machine capacity (number of machines) and probability that COVID-19 recovered individuals are willing to donate were the most important supply-side drivers of ability to meet demand. Recruitment capacity was important in states with early peaks.

Conclusions Epidemic trajectory was the most important determinant of ability to meet demand for CCP, although our simulations revealed several contributing operational drivers of CCP program success.

Competing Interest Statement

W.A.R. and B.C. have provided consulting services outside the submitted work for Terumo BCT, a manufacturer of apheresis equipment.

Funding Statement

This work was funded by Vitalant.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Not applicable

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

We have shared all code and data in a public repository except for the individual donor return data. https://doi.org/10.5281/zenodo.4082755.

https://doi.org/10.5281/zenodo.4082755

https://github.com/vitalantri/ccp_model

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 27, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Factors driving availability of COVID-19 convalescent plasma: Insights from a demand, production and supply model
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Factors driving availability of COVID-19 convalescent plasma: Insights from a demand, production and supply model
W. Alton Russell, Eduard Grebe, Brian Custer
medRxiv 2020.10.25.20219170; doi: https://doi.org/10.1101/2020.10.25.20219170
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Factors driving availability of COVID-19 convalescent plasma: Insights from a demand, production and supply model
W. Alton Russell, Eduard Grebe, Brian Custer
medRxiv 2020.10.25.20219170; doi: https://doi.org/10.1101/2020.10.25.20219170

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Economics
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1096)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9767)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1559)
  • Health Policy (735)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11641)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2142)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (517)
  • Oncology (1176)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4657)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)